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Abstract
Purpose: Imatinib Mesylate (Gleevec) is a drug that potently counteracts diabetes both in humans and in animal models for
human diabetes. We have previously reported that this compound in human pancreatic islets stimulates NF-kB signaling
and islet cell survival. The aim of this study was to investigate control of NF-kB post-translational modifications exerted by
Imatinib and whether any such effects are associated with altered islet gene expression and chemokine production in vitro.
Procedures: Human islets were either left untreated or treated with Imatinib for different timepoints. IkB-a and NF-kB p65
phosphorylation and methylation were assessed by immunoblot analysis. Islet gene expression was assessed using a
commercial Pathway Finder microarray kit and RT-PCR. Islet chemokine production was determined by flow cytometric
bead array analysis.
Findings: Human islet IkB-a and Ser276-p65 phosphorylation were increased by a 20 minute Imatinib exposure.
Methylation of p65 at position Lys221 was increased after 60 min of Imatinib exposure and persisted for 3 hours. Microarray
analysis of islets exposed to Imatinib for 4 hours revealed increased expression of the inflammatory genes IL-4R, TCF5, DR5,
I-TRAF, I-CAM, HSP27 and IL-8. The islet release of IL-8 was augmented in islets cultured over night in the presence of
Imatinib. Following 30 hours of Imatinib exposure, the cytokine-induced IkB-a and STAT1 phosphorylation was abolished
and diminished, respectively. The cytokine-induced release of the chemokines MIG and IP10 was lower in islets exposed to
Imatinib for 30 hours.
Conclusion: Imatinib by itself promotes a modest activation of NF-kB. However, a prolonged exposure of human islets to
Imatinib is associated with a dampened response to cytokines. It is possible that Imatinib induces NF-kB preconditioning of
islet cells leading to lowered cytokine sensitivity and a mitigated islet inflammation.
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Introduction
Type 1 diabetes is an autoimmune disease in which dysfunction
and damage of insulin-producing beta-cells is thought to arise from
direct contact with immune cells and from exposure to cytotoxic
pro-inflammatory cytokines and other toxic substances [1]. In
Type 2 diabetes beta-cells are also dysfunctional and damaged,
possibly in response to peripheral insulin resistance, hyperglyce-
mia, hyperlipidemia and cytokines, leading to a relative lack of
insulin [2]. The molecular events leading to diabetes-associated
beta-cell dysfunction and death have been investigated and it
appears that the activation of the transcription factor Nuclear
factor kappa B (NF-kB), in response to both inflammation,
amyloidogenic peptides and oxidative stress, plays a central role in
this chain of events [1].
The transcription factor NF-kB is activated by different
mitogenic stimuli, stress signals, or inflammatory cytokines in a
broad range of cell types [3,4]. The classical NF-kB pathway
involves the NF-kB precursor protein p105 (NF-kB-1) [5]. This
protein is processed to the mature p50 NF-kB-1 that preferentially
heterodimerizes with other members of the NF-kB family, i.e. p65,
c-Rel or Rel-B. Activation of the classical pathway involves release
of p50/p65 from IkB-a, as a result of phosphorylation by the IkB
kinase and degradation of IkB-a by the proteasome. The mature
dimeric NF-kB proteins then translocate to the nucleus and
activate genes involved in anti-apoptotic function, the modulation
of immune and inflammatory response, cell proliferation,
adhesion, and angiogenesis [6].
The drug Imatinib mesylate (Gleevec) is currently used as
treatment of chronic myeloid leukemia (CML), Gastrointestinal
stromal tumor (GIST) and other malignancies, diseases caused by
the Bcr-Abl oncogene, c-Kit mutations or other tyrosine kinase
mutations. Imatinib binds to and stabilizes the inactive form of
Bcr-Abl, which leads to annulation of the effects of the Bcr-Abl
oncoprotein through the inhibition of Bcr-Abl autophosphory-
lation and substrate phosphorylation [7]. Imatinib is the first
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kmember of a new class of agents that act by specifically inhibiting a
certain mutated enzyme that is characteristic of a particular cancer
cell, rather than non-specifically inhibiting and killing all rapidly
dividing cells, and it reached clinical practice some 10 years ago.
It has recently been observed that patients suffering from both
leukemia and diabetes were cured from not only leukemia, but also
diabetes, when treated with Imatinib [8–10]. Although two
subsequent studies found no effect of Imatinib on Type 2 diabetes
[11,12], other additional studies report anti-hyperglycemic/anti-
diabetic effects of Imatinib or similar tyrosine kinase inhibitors in
humans [13–20]. These clinical studies clearly demonstrate that
although not all Type 2 diabetes patients benefit from Imatinib
therapy, there is a substantial proportion that responds, and some
cases so dramatically that they become insulin-independent. An
anti-diabetic action of Imatinib in Type 2 diabetes is further
supported by our recent observation that Imatinib counteracts
high-fat diet induced insulin resistance and hyperglycemia in rats
[21]. Moreover, in a study from 2009, Imatinib was also observed
to induce remission of diabetes in db/db mice, possibly via
decreasing insulin resistance and increasing the beta-cell mass
[22]. Also, Imatinib has been demonstrated to counteract
streptozotocin-induced diabetes in rats [23]. Thus, in both animal
models and in Type 2 diabetes patients Imatinib seems to improve
glycemic control, possibly via an insulin sensitizing effect.
Imatinib appears to prevent and reverse not only Type 2
diabetes, but also diabetes of animal models with a Type 1 diabetes
resembling disease. We have shown that Imatinib protects against
beta-cell death in vitro and prevents diabetes in NOD mice and in
streptozotocin-diabetic mice, both models for human beta-cell
destruction and Type 1 diabetes [24,25]. More recently, it has
been observed that both Imatinib and Sunitinib not only
prevented, but also reversed new-onset diabetes in NOD mice
[26]. Thus, there exists proof-of-principle in animal models for an
anti-diabetic effect of Imatinib and similar tyrosine kinase
inhibitors, and that a limited treatment period will not only
reverse diabetes, but also mediate long-term protection against re-
precipitation of the disease [26]. This has led us [27] and other
investigators [28,29] to propose clinical trials in which Imatinib is
given to new-onset Type 1 diabetes patients.
We have previously reported that Imatinib-mediated protec-
tion against human islet cell death was paralleled by increased
IkB degradation [25]. We have also observed that increased NF-
kB activity in human islet cells resulted in enhanced survival in
response to different beta-cell toxins [30]. Thus, Imatinib may
promote beta-cell survival by increasing expression of NF-kB
induced anti-apoptotic genes. The effects of Imatinib on human
islet inflammation are, to our knowledge, unknown. Therefore,
we presently investigated human islet IkB/NF-kB phosphoryla-
tion, acetylation and methylation, and studied whether islet gene
expression and chemokine production was affected by Imatinib
treatment. We report that Imatinib promoted a modest and rapid
increase in IkB phosphorylation, p65 phosphorylation and p65
methylation. Imatinib also enhanced expression of NF-kB
responsive inflammatory genes and increased production of the
chemokine IL-8. We also observe that a prolonged Imatinib
exposure preconditioned the islet cells so that the cytokine
response, as assessed by both IkB and STAT1 phosphorylation
and chemokine production, was attenuated. We propose that the
Imatinib-mediated increase in NF-kB results in human islet
desensitization to cytokines and decreased islet inflammation.
These finding may improve our understanding of the mecha-
nisms by which Imatinib counteracts both Type 1 and Type 2
diabetes.
Materials and Methods
Islet isolation, culture, and exposure to different beta-cell
inhibitory substances
Human pancreatic islets were kindly provided by Prof. Olle
Korsgren (Dept. of Radiology, Oncology and Clinical Immunol-
ogy, Uppsala University Hospital, Uppsala, Sweden) through the
Nordic Network for Clinical Islet Transplantation. Only organ
donors who had agreed to donate for scientific purposes were
included. Informed written consent to donate organs for medical
and research purposes was obtained from donors, or relatives of
donors, by the National Board of Health and Welfare (Socialstyr-
elsen), Sweden. Permission to obtain pancreatic islet tissue from
the Nordic Network for Clinical Islet Transplantation was
reviewed and approved by the local ethics committee (Regionala
etikpro ¨vningsna ¨mnden, Uppsala) in Uppsala, Sweden. The
human pancreatic islets were isolated from the pancreas of
brain-dead organ donors using collagenase digestion and Biocoll
gradient centrifugation [31].
After isolation, the islets were cultured free-floating in Sterilin
dishes in CMRL 1066 medium containing 5.6 mM glucose, 10%
fetal calf serum (FCS), and 2 mM L-glutamine for 1–5 days.
The islet beta-cell percentages determined using Newport
Green staining followed by fluorescence microscopy were
routinely 30–60%. To evaluate islet functional quality, batches
of twenty islets were perfused with Krebs-Ringer bicarbonate
HEPES buffer (KRBH) containing 2 mg/ml human albumin and
1.67 mmol/l glucose at a flow rate of 0.3 ml/min. The glucose
concentration was increased to 16.7 mM after a 30-min period.
Fractions for insulin measurement were collected every 4 min.
Only islet preparations that responded to a high glucose challenge
with a more than doubled insulin release were used for further
experimentation.
Following the initial culture period, islets were cultured for an
additional 6–24 hours in CMRL 1066 containing antibiotics,
2 mM glutamine and one of the following supplements: 0.5 mM
sodium palmitate solubilized in 0.5% (weight/volume) fatty acid
and lipopolysaccaride free bovine serum albumin (BSA) (Sigma);
recombinant human Interleukin 1beta (IL-1ß (50 units/ml)
(PeproTech, London, U.K.) and Interferon-gamma (IFN-c)
(1,000 units/ml) (PeproTech); 100 mM hydrogen peroxide;
2 mM DETA/NO (Cayman Chemicals) or 10 mM streptozotocin
(STZ) (Sigma). To some of the groups 10 mM of Imatinib was
added at different time points prior to the addition of test
substances given above. To controls equal amounts of vehicle
(DMSO) were supplemented.
RNA isolation and cDNA synthesis
Total RNA was isolated from human pancreatic islet using the
Ultraspec
TM RNA Isolation System reagent (Biotecx Laboratories,
Houston, TX, USA). Two mg of RNA was used for cDNA
synthesis. cDNA was synthesized using the M-MuLV reverse
transcriptase (Finnzymes, Espoo, Finland) and oligo-dT primers
according to the manufacturer’s instructions.
Real-time PCR
PCR amplification was performed using the Lightcycler
instrument (Roche Diagnostics, Lewes, UK) and the Lightcycler
FastStart DNA Master SYBR Green I kit (Roche Diagnostics). The
following primers were used: GAPDH (human) (glyceraldehyde-3-
phosphate dehydrogenase): 59-ACCACAGTCCATGCCATCAC
(forward) 59-TCCACCACCCTGTTGCTGTA (reverse), IL-8
(human) 59-GGCAACCCTACAACAGACCCACA (forward),
TGCTAACAGGCTTAGGACTTGC (reverse). Semi-quantitative
Imatinib Mesylate and NF-kB
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2
crossing point GAPDH - crossing point IL-8.
Immunoblot analysis
Islets in groups of 50 were washed once with PBS and then lysed
with SDS sample buffer; 2% SDS, 5% b-mercaptoethanol,
100 mM Tris-HCL pH 6.8, 10% glycerol and bromophenolblue.
The protein samples were boiled for 5 min before separation on a
9% SDS-PAGE. The separated proteins were electrophoretically
transferred to Hybond
TM-P membranes (Amersham Bioscience),
which were then pre-blocked in 5% BSA. The membranes were
hybridized with monoclonal mouse or polyclonal rabbit antibodies
directed against IkB-a (C-21, Santa Cruz), Phospho-Ser32- IkB-a
(Cell Signaling), Acetylated-Lys310-p65 (Abcam), Phospho-
Ser276-p65 (Santa Cruz), Phospho-Ser536-p65 (Cell Signaling),
p65 (F-6, Santa Cruz), Methyl-Lys221-p65 [32] or Phospho-
Tyr701-STAT1 (Cell Signaling) over night at 4uC. The horserad-
ish peroxidase conjugated anti-mouse or anti-rabbit antibodies
were used as secondary antibodies and luminescence detected with
the ECL system (Amersham Bioscience). The resulting bands were
then digitalized using the Kodak 4000MM system and the optical
densities were measured using the Kodak Molecular Imaging
Software.
Extraction of nuclear proteins and electromobility shift
assay (EMSA)
INS-1 832/13 cells were treated with Imatinib (10 mM) for 1 or
24 hours and IL-1ß (50 U/ml)+IFN-c (1000 U/ml) for 30 min,
after which nuclear proteins were extracted for EMSA, which was
performed as previously described [32]. The kB-binding activity of
the nuclear extracts was determined using the LightShift
Chemiluminescent EMSA Kit (Pierce Biotechnology) according
to the instructions of the supplier. As labeled probe, a double-
stranded biotin-labeled oligonucleotide with the sequence 59-
AGTTGAGGGGACTTTCCCAGGC was used. The resulting
bands were digitalized using the Kodak 4000MM system and the
optical densities were measured using the Kodak Molecular
Imaging Software.
Microarray analysis
Human islets in groups of 1000 were either treated with DMSO
or with 10 mM Imatinib for 4 hours. Following the treatments,
total RNA was isolated using the Ultraspec
TM RNA Isolation
System reagent (Biotecx Laboratories, Houston, TX, USA). The
RNA was then converted to biotin-labelled cRNA using the
TrueLabeling-AMP
TM Linear RNA Amplification Kit (SABios-
ciences) and hybridized overnight to the the Oligo GEArray
Human Signal Transduction Pathway Finder Microarray filters
(SABiosciences). Signals from the filters were detected by
luminescence and quantified by densitometry using the Kodak
4000MM system and Kodak Molecular Imaging Software, all
according to the to the instructions of the supplier (SABiosciences).
Chemokine analysis
Human islets in groups of 50 were cultured in 0,5 ml CMRL
1066. The islets were pre-cultured for 6 hours with our without
10 mM of Imatinib and then cultured for another 24 hours with
either 100 mM hydrogen peroxide, 10 mM streptozotocin, 1 mM
DETA/NO or cytokines (50 U/ml IL-1ß+1000 U/ml IFN-c).
Islet culture medium was then recovered and analyzed for
interleukin-8 (CXCL8/IL-8), RANTES (CCL5/RANTES),
monokine induced by interferon-c (CXCL9/MIG), monocyte
chemoattractant protein-1 (CCL2/MCP-1), and interferon-c–
induced protein-10 (CXCL10/IP-10) levels using the BD
Cytometric Bead Array Human Chemokine Kit according to
the instructions of the supplier (Becton Dickinson).
Results
Imatinib induces a rapid increase in IkB-a
phosphorylation, ser276-p65 phosphorylation and
lys221-p65 methylation
We have previously reported that Imatinib promoted IkB-a
degradation in human islets [25]. To better understand the effects
of Imatinib on human islet NF-kB activation, we first performed
time course studies of IkB-a phosphorylation, Ser276-p65
phosphorylation, Ser536-p65 phosphorylation, Lys310-p65 acety-
lation and Lys221-p65 methylation. These are all NF-kB-
associated post-translational modifications that have been reported
to stimulate NF-kB activity [33–36]. We observed that IkB-a
phosphorylation was significantly increased at 20 min of Imatinib
(10 mM) exposure (Figure 1). At later time points there was a trend
to increased IkB-a phosphorylation, but it did not reach statistical
significance, probably due to the low number of observations.
Ser276-phosphorylated p65 migrated slightly slower (72 kDa) than
non-ser276-phosphorylated p65 (68 kDa), and the intensity of the
P-ser276-p65 band was weak. This indicates that P-ser276-p65
constitutes a minor proportion of all p65 and this fraction could
represent the transcriptionally active form of p65. The phosphor-
ylation of p65 at position Ser276 was increased by Imatinib at
20 min (Figure 1). At 60–360 min, however, the ser276-p65
phosphorylation was no longer increased, indicating that Imatinib-
induced ser276-p65 phosphorylation is transient. P-Ser536-p65
immunoblotting signals were strong and P-ser536-p65 migrated to
the same position as total p65. This finding is consistent with the
view that p65 is constitutively phosphorylated at position ser536 in
human islets, and that this post-translational modification has
limited regulatory importance. Indeed, Imatinib did not stimulate
ser536-p65 phosphorylation; instead there was a trend towards
decreased ser536-p65 phosphorylation with increasing exposure
time to Imatinib (Figure 1). Methylation of p65 as position lys221
was not affected by Imatinib at 20 min. However, at both 60 and
180 min Imatinib promoted a modest increase in p65 methylation
(Figure 1), which was less pronounced than that of cytokines
(results not shown). Finally, we probed for effects of Imatinib on
p65 Lys310 acetylation. However, we could not detect specific
immunreactivity for Ac-lys310-p65 in human islets, neither under
conditions of Imatinib exposure or when stimulated by cytokines
(results not shown). It is not clear whether the lack of Ac-p65 signal
is due to a low sensitivity of the Abcam anti-Ac-p65 antibody, or to
a constitutively low p65 acetylation activity in human islets.
Four hours of Imatinib exposure results in increased
expression of inflammatory genes
To verify that the observed effects of Imatinib on human islet
IkB-a and p65 phosphorylation/methylation events result in
increased NF-kB target gene transcription, we performed a
microarray analysis. Human islets were exposed to vehicle or
Imatinib for 4 hours and then analyzed using the Oligo GEArray
Human Signal Transduction Pathway Finder Microarray. By this
approach we observed that 10 genes were increased more than
30% in response to the Imatinib treatment (Table 1). Out of these
10 genes 7 are typical inflammatory or stress genes (IL-4R, TCF5,
DR5, I-TRAF, I-CAM, HSP27 and IL-8), indicating that Imatinib
promoted transcription of NF-kB target genes.
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induced IkB-a and ser276-p65 phosphorylation
Because IkB-a and ser276-p65 phosphorylation were stimulated
by Imatinib (Figure 1), we next investigated whether cytokine-
induced IkB-a and ser276-p65 phosphorylation was affected by
Imatinib treatment. We also studied the effects of sodium palmitate,
since it hasbeenreported that this saturatedfreefatty acid promotes
NF-kB activation in human beta-cells [37]. We observed that a
20 min exposure to the combination of IL-1ß (50 U/ml) and IFN-c
(1000 U/ml) increased IkB-a phosphorylation (Figure 2). Some-
what surprisingly, sodium palmitate was without effect (Figure 2).
Similar to the results of Figure 1, a 6-hour Imatinib pre-exposure
promoted an increased IkB-a phosphorylation. Interestingly,
cytokine-induced IkB-a phosphorylation in the presence of
Imatinib was not further increased as compared to Imatinib only
(Figure 2). Using the same experimental setup as in Figure 2, we
observed that cytokines also promote phosphorylation of ser276-
p65 (Figure 3). Cytokine-induced ser276-p65 phosphorylation was
not affected by the 6-hour Imatinib pretreatment (Figure 3). Thus,
at the 6-hour time point, cytokine-induced IkB-a and ser276-p65
phosphorylation is not further potentiated by Imatinib.
Over-night exposure to Imatinib results in attenuation of
cytokine-induced IkB-a and STAT1 phosphorylation
To clarify whether a prolonged (over-night) Imatinib-exposure
period affects cytokine-induced signaling, we pre-exposed human
islets to Imatinib for 6 hours and then continued the culture period
for another 24 hours with and without both Imatinib and the
combination ofIL-1ß and IFN-c.Inthis situationhumanisletIkB-a
phosphorylationwas enhanced in cells exposed to cytokines, but not
Figure 1. Effects of Imatinib on human islet IkB-a and NF-kB p65 phosphorylation/methylation. Human islets in groups of 50 were
cultured in the presence of vehicle (DMSO) or 10 mM of Imatinib at the times given in the Figure. Islets were washed and harvested for SDS-PAGE and
immunoblotting with anti-IkB-a and p65 antibodies. Phospho- and methylation-bands were quantified and normalized to total IkB-a and p65 bands.
The lower panel shows immunoreactivity from one representative experiment. Results are means 6 SEM for 4 independent experiments. * denotes
p,0.05 using paired Student’s t-test when comparing vs. control.
doi:10.1371/journal.pone.0024831.g001
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GeneBank Description Gene Name
Fold induction
(Imatinib vs control)
NM_000418 Interleukin 4 receptor IL-4 Ra 1.64
NM_005526 Heat shock transcription factor 1 Tcf5 1.48
NM_003842 Tumor necrosis factor receptor superfamily, member 10b KILLER/DR5/TRAILR2 1.40
NM_004180 TRAF family member-associated NF-kB activator I-TRAF 1.39
NM_000201 Intercellular adhesion molecule 1 (cd54), human rhinovirus receptor ICAM-1 1.36
NM_002539 Ornithine decarboxylase 1 ODC1 1.34
NM_001540 Heat shock 27 kDa protein 1 HSP28/HSP27/Hsp25 1.33
NM_000584 Interleukin 8 IL-8 1.32
NM_005967 NGFI-A binding protein 2 (DGR1 binding protein 2) NAB2 1.32
NM_001552 Insulin-like growth factor binding protein 4 IGFBP-4 1.31
Human islets in groups of 1000 were exposed to DMSO (control) or to 10 mM of Imatinib for 4 hours. Following treatments, RNA was isolated, converted into cRNA and
hybridized to Oligo GEArray Human Signal Transduction Pathway Finder Microarray filter according to the instructions of the supplier. The filters were scanned in a
Kodak 4000MM Image station. Results from two independent experiments were analyzed by measuring the optical densities of the spots using the Kodak Molecular
Imaging Software. Optical densities were normalized to housekeeping genes included on the filter (ribosomal protein S27a, GAPDH, beta-actin). Table shows the mean
fold induction from the two separate experiments and only genes increased with more than 30% are shown.
doi:10.1371/journal.pone.0024831.t001
Figure 2. Effects of cytokines, palmitate and Imatinib on
human islet IkB-a phosphorylation. Human islets in groups of 50
were pre-cultured for 6 hours with our without 10 mM of Imatinib and
then stimulated with either 0.5 mM sodium palmitate or 50 U/ml IL-
1b+1000 U/ml IFN-c for 20 min. Islets were washed and harvested for
SDS-PAGE and immunoblotting with anti-P-IkB-a and total IkB-a
antibodies. Phospho-bands were quantified and normalized to total
IkB-a bands. The lower panel shows immunoreactivity from one
representative experiment. Results are means 6 SEM for 4 independent
experiments. * denotes p,0.05 using paired Student’s t-test when
comparing vs. control.
doi:10.1371/journal.pone.0024831.g002
Figure 3. Effects of cytokines and Imatinib on human islet NF-
kB p65 phosphorylation. Human islets in groups of 50 were pre-
cultured for 6 hours with our without 10 mM of Imatinib and then
stimulated with 50 U/ml IL-1b+1000 U/ml IFN-c for 20 min. Islets were
washed and harvested for SDS-PAGE and immunoblotting with anti-P-
Ser276-p65 and total p65 antibodies. Phospho-bands were quantified
and normalized to total p65 bands. The lower panel shows
immunoreactivity from one representative experiment. Results are
means 6 SEM for 3 independent experiments. * denotes p,0.05 using
paired Student’s t-test when comparing vs. control.
doi:10.1371/journal.pone.0024831.g003
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Interestingly, also cytokine-induced STAT1 phosphorylation was
weakened by Imatinib (Figure 4B). Thus, a prolonged Imatinib
exposure resulted in attenuation of cytokine-induced signaling
events.
We also tested whether human islet IkB-a phosphorylation was
affected by the beta-cell toxins hydrogen peroxide, which induces
oxidative stress, streptozotocin, which induces alkylation of
macromolecules and NAD+ depletion, and DETA/NO, which
induces nitrosative stress. As we have previously observed that beta-
cell death induced by these toxins is counteracted by Imatinib
[24,25], it could be hypothesized that stressed beta-cells activate
NF-kB and that thisevent is modulated byImatinib. Although these
substances tended to increase IkB-a phosphorylation, there were no
significant effects, either induced by themselves or in combination
with Imatinib (Figure 4A). Moreover, STAT1 phosphorylation was
undetectable in all groups other than the cytokine-treated islets
(Figure 4B). The limited access of human islet material precludes a
more sensitive and careful analysis of these parameters, something
that isprobablynecessarytosuccessfullydetectmodestalterationsin
NF-kB and STAT1 signaling.
Imatinib increases basal and decreases cytokine-induced
chemokine release
To obtain a functional read-out of Imatinib-modulated NF-kB
signalingevents, we analyzed human islet chemokine release using a
flow cytometric bead assay for the chemokines IP10, IL-8, MCP-1,
RANTES and MIG. The experimental setup was the same as for
Figure 4, i.e. human islets were pre-exposed to Imatinib for 6 hours
and then cultured for another 24 hours with or without Imatinib
and hydrogen peroxide, streptozotocin and DETA/NO (Figure 5),
or with or without Imatinib and cytokines (Figure 6). We observed
that islet release of the chemokine IL-8 to the culture medium was
increased by Imatinib (Figure 5A). This observation corroborates
the Imatinib-induced expression of IL-8 mRNA assessed by
microarray analysis (Table 1). The beta-cell cytotoxic agents
hydrogen peroxide,streptozotocin and DETA/NO didnot increase
human islet release of IL-8 (Figure 5A), which is in agreement with
our observation that IkB-a and STAT1 phosphorylation were not
affected by these toxins (Figure 4). Imatinib increased the release of
IL-8 also in islet cells exposed to hydrogen peroxide and DETA/
NO (Figure 5A), supporting the notionthat Imatinib enhances basal
NF-kB activity and chemokine release. Due to large error bars,
there were no significant effects of Imatinib and the cytotoxic agents
on IP10 (Figure 5B) and MCP-1 (Figure 5C) release. Nevertheless,
there was a trend to higher IP10 and MCP-1 release in response to
Imatinib, also supporting an NF-kB stimulatory effect of Imatinib.
The levels of MIG and RANTES were barely detectable and we
could not observe any effects on the release of these chemokines
(results not shown).
The release of IL-8, IP10, MIG and MCP-1, but not of
RANTES, was dramatically (100–1000-fold) increased by the
cytokines IL-1ß and IFN-c (Figure 6). Interestingly, Imatinib
decreased the cytokine-induced release of IP10 and MIG, and
tended to decrease MCP-1 and IL-8 release (Figure 6). Thus, a
prolonged Imatinib exposure decreased both cytokine-induced
transcription factor phosphorylation (Figure 4) and chemokine
release. To validate the results obtained from the microarray and
the chemokine release kit, we analyzed IL-8mRNAlevels in human
islets using real time PCR. Imatinib exposure for 30 hours resulted
in a 8-fold induction of IL-8 mRNA levels when compared to
control. (Figure 6 B). Cytokine (IL-1ß and IFN-c) treatment for
30 hours led to a strong induction (over a 35-fold) of IL-8 mRNA
levels. (Figure 6 B). However when pretreated with Imatinib, the
Figure 4. Effects of cytokines, hydrogen peroxide, STZ, DETA/
NO and Imatinib on human islet IkB-a (A) and STAT1 (B)
phosphorylation. Human islets in groups of 50 were pre-cultured for
6 hours with our without 10 mM of Imatinib and then cultured for
another 24 hours with either 50 U/ml IL-1b+1000 U/ml IFN-c (cyto-
kines), 100 mM hydrogen peroxide (H2O2), 10 mM streptozotocin (STZ)
or 1 mM DETA/NO. Islets were washed and harvested for SDS-PAGE and
immunoblotting with anti-P-IkB-a and total IkB-a antibodies (A) or anti-
P-STAT1 and total p65 antibodies (B). Phospho-bands were quantified
and normalized to total IkB-a or total p65 bands. The lower panels
show immunoreactivity from one representative experiment. Results
are means 6 SEM for 3 independent experiments. * denotes p,0.05
using paired Student’s t-test when comparing vs. control.
doi:10.1371/journal.pone.0024831.g004
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(Figure 6 B). The result from real time PCR are in concert with the
chemokine release and microarray data, further strengthening the
notion that a prolonged Imatinib exposure dampens the cytokine-
induced chemokine release in human islets.
Prolonged Imatinib exposure leads to decreased kB-
binding in in INS-1 832/13 cells
Human islets consist of 30–60% beta-cells. However they also
contain other endocrine cells such as alpha- and delta-cells. To
confirm that the observed effects of Imatinib on NF-kB activation
Figure 5. Effects of hydrogen peroxide, STZ, DETA/NO and Imatinib on human islet IL-8 (A), IP10 (B) and MCP-1 (C) release. Human
islets in groups of 50 were pre-cultured for 6 hours with our without 10 mM of Imatinib and then cultured for another 24 hours with either 100 mM
hydrogen peroxide (H2O2), 10 mM streptozotocin (STZ) or 1 mM DETA/NO. Islet culture medium was then recovered and analyzed for IL-8 (A), IP10
(B) and MCP-1 (C) contents using a flow cytometry cytometric bead assay. Results are expressed in arbitrary units and are means 6 SEM for 3
independent experiments. * denotes p,0.05 using paired Student’s t-test when comparing vs. control.
doi:10.1371/journal.pone.0024831.g005
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mobility shift assay (EMSA) on nuclear extracts from the INS-1
832/13 beta-cell line. Cytokine (IL-1b and IFN-c) exposure for
20 min resulted in a significant increase in kB-binding activity in
INS-1 832/13 nuclear extracts (Figure 7). A short time Imatinib
exposure (1 hour) tended to increase the kB-binding activity
(p=0.06) whereas a long exposure (24 hours) of INS-1 cells to
Imatinib resulted in a significant decrease of kB-binding activity
(Figure 7). These results strengthen the idea that a short-term
exposure to Imatinib results in a modest activation of NF-kB,
Figure 6. Effects of cytokines and Imatinib on human islet chemokine release and on IL-8 mRNA levels. A. Human islets in groups of 50
were pre-cultured for 6 hours with our without 10 mM of Imatinib and then cultured for another 24 hours with 50 U/ml IL-1b+1000 U/ml IFN-c
(cytokines). Islet culture medium was then recovered and analyzed for the chemokines IP10 and MCP-1, MIG, RANTES and IL-8 contents using a flow
cytometry cytometric bead assay. Results are expressed in arbitrary units and are means 6 SEM for 3 independent experiments. * denotes p,0.05
using paired Student’s t-test when comparing vs. control. B. Human islets in groups of 30 were left untreated or treated with Imatinib (10 mM,
30 hours) or cytokines (50 U/ml IL-1b+1000 U/ml IFN-c, 24 hours). In the Imatinib+cytokines group, islets were pretreated with Imatinib for 6 hours
followed by a 24 hours exposure to cytokines. Following treatments, RNA was isolated and cDNA synthesized and IL-8 levels analyzed using real time
PCR. Figure shows fold induction when normalized to GAPDH. Results are means 6 SEM for 4 independent experiments. * denotes p,0.05 using
paired Student’s t-test when comparing vs. control.
doi:10.1371/journal.pone.0024831.g006
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tion in beta-cells.
Discussion
We presently report that both Imatinib and the cytokines IL-1b
and IFN-c increase IkB-a phosphorylation, ser276-p65 phosphor-
ylation and lys221-p65 methylation. The cytokine-induced
phosphorylation of IkB-a in insulin producing cells has previously
been reported [3–5], but the methylation event is, to our
knowledge, a novel finding. The methylation of p65 at position
lys221 appears to be a necessary event for mouse embryo
fibroblast p65-dependent gene expression, and may be carried
out by a lysine methylase, the nuclear receptor–binding SET
domain-containing protein 1 (NSD1) [33]. The demetylation is
probable carried out by the lysine demethylase F-box and leucine-
rich repeat protein 11 (FBXL11), a protein that is induced by NF-
kB and therefore functions as a negative feedback mechanism
[33]. The present findings indicate that this NF-kB regulatory
mechanism is probably operational in human islet cells and that
both cytokines and Imatinib stimulate NF-kB activity by
enhancing p65 methylation. Although the mechanisms underlying
increased p65 methylation remain to be elucidated, immunoblot
assessment of p65 methylation could provide a convenient and
accurate alternative to other technique currently used for the
detection of islet NF-kB activation.
Also the increased phosphorylation of p65 at position ser276
points to an NF-kB stimulating effect of Imatinib. A previous
publication has reported that IL-1b -induced NF-kB activity in
insulin-producing cells requires p65 phosphorylation at position
ser276, but not at ser536 and ser529 [34]. This is in agreement
with our present finding that both cytokines and Imatinib
stimulated ser276, but not ser536 phosphorylation. Ser536
phosphorylation may require the PI3K/PKB pathway [35],
whereas ser276 phosphorylation of p65 may result from activation
of PKA [36], MSK1 [37] or Pim-1 [38]. We have previously
observed that cytokines activate the p38MAPK/MSK1 pathway
in insulin producing cells [39], indicating that cytokine-induced
p65 phosphorylation involves p38MAPK/MSK1 activity rather
than PI3K/PKB. P38MAPK has also been reported to promote
p300 association with p65 and the subsequent acetylation of p65 at
position lys310 [40]. Although we did not observe p65 acetylation
in human islets, we cannot exclude the possibility that this occurs,
and we hope that the future availability of a more sensitive p65
acetylation antibody might resolve this question.
We verified Imatinib-induced activation of human islet NF-kB
by microarray, real-time PCR and measurement of chemokine
release. These approaches identified the chemokine IL-8, which is
a well-known NF-kB target gene in islet cells [41], to be induced
by Imatinib. However, the Imatinib-induced increase in IL-8 was
very modest - 2-fold - as compared to the effect of cytokines, which
was almost 1000-fold. This may indicate that other NF-kB
synergizing signaling pathways are activated by the cytokines IL-
1b and IFN-c, for example IRF-1 and STAT1, and that the effect
of Imatinib is too weak to promote clinical inflammation.
Of greater functional importance appears to be the Imatinib-
induced decrease in cytokine-induced chemokine release. Cyto/
Chemokines can exert both beneficial and detrimental effects on
islets. For example, short time exposure of islets to IL-1b promotes
beta-cell replication and insulin secretion whereas exposure for
longer time periods leads to beta-cell death [42]. Islet cells,
including beta-cells, produce a variety of chemokines that are
necessary for maintaining beta-cell function and mass. However, if
the cytokine balance is disturbed, an inflammatory response within
the islet can damage or in the worst case destroy the islet. We
report that Imatinib significantly decreased the cytokine-induced
release of the chemokines MIG and IP10 and, although not
reaching statistical significance, tended to dampen the release of
IL-8. IP10, MIG and IL-8 belong to the CXC family of
chemokines and increased levels have been associated with islet
inflammation and Type 1 and Type 2 diabetes in both animal
models and in humans [43]. One could therefore speculate that
the observed antidiabetic effects of Imatinib in vivo in part could
be due to a lowered islet secretion of the above chemokines.
Although the effects of Imatinib NF-kB activation were validated
using a beta-cell line, we cannot exclude that Imatinib modulates
NF-kB activity in other islet cells in a similar way.
Our results point to the possibility that the Imatinib-mediated
increase in basal NF-kB activity stimulates NF-kB-induced
negative feedback signals that dampen the cytokine-mediated
inflammatory response (Figure 8). Examples of such negative
feedback mechanisms are the above-mentioned FBXL11 de-
methylase [33], NF-kB -induced IkB-gene transcription, IkK-b -
induced A20 phosphorylation [44,45], SOCS3 [46] and ABIN1-3
[47]. In addition, the scaffold protein I-TRAF has recently been
reported to inhibit NF-kB activation by recruiting polo-like kinase
1 [48], and IL-4R-mediated STAT6 activation has been shown to
prevent p65 nuclear translocation [49]. Interestingly, we presently
observed induction of I-TRAF and IL-4R mRNA in response to
Imatinib. Thus, it is tempting to speculate that a long-term
Imatinib exposure enhances I-TRAF and IL-4R expression, which
will in the long term negatively regulate cytokine-induced NF-kB
activation.
The precise molecular targets for Imatinib that mediate
modulation of NF-kB activity in human islet cells are unknown.
Imatinib is known to inhibit the tyrosine kinases c-Abl, PDGFR, c-
Figure 7. Effects of Imatinib on kB-binding activity in INS-1
nuclear extract. INS-1 832/13 cells were left untreated (control),
treated with cytokines (50 U/ml IL-1b+1000 U/ml IFN-c for 30 min or
treated with 10 mM Imatinib for 1 or 24 hours. Nuclear extracts were
prepared and NF-kB activity was determined by EMSA. The upper panel
shows densitometric scanning results 6 SEM for 3 separate experi-
ments. * denotes p,0.05 versus control using Student’s t-test.
doi:10.1371/journal.pone.0024831.g007
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interest because it is known that c-Abl suppresses basal NF-kB
activity in mouse embryonic fibroblasts [50]. C-Abl seems to
promote both tyrosine phosphorylation of IkB-a and downregu-
lation of the histone deacetylase HDAC1, a negative regulator of
NF-kB [50]. It has therefore been suggested that the proapoptotic
activity of c-Abl may be mediated by downregulation of NF-kB
activity [50]. The findings of this study suggest that not only c-Abl
mediated apoptosis [24], but also c-Abl control of chemokine
production is targeted by Imatinib treatment.
In summary, we presently observe that Imatinib in human islets,
possibly via inhibition of c-Abl, initially promotes an increased
basal NF-kB activity, which is followed by, somewhat paradox-
ically, a second stage characterized by a lowering in the sensitivity
to cytokines. This may result in two beneficial effects in diabetes:
Firstly, induction of anti-apoptotic genes will probably stimulate
beta-cell survival and insulin production. Secondly, lowered
cytokine sensitivity might decrease islet leukocyte infiltration,
amyloid formation and beta-cell exhaustion. Both effects may
contribute to the observed anti-diabetes effects of Imatinib in
humans and in animal models for Type 1 and Type 2 diabetes.
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